**Combined analysis of expression, prognosis and immune infiltration of GINS family genes in human sarcoma**

Kexin Zhang¹,²,*, Jian Zhou¹,*, Tong Wu¹, Quynan Tian¹, Tang Liu¹, Wanchun Wang¹, Hua Zhong³, Ziyuan Chen⁴,⁵*, Xungang Xiao⁴, Gen Wu³

¹Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
²Department of Psychology, School of Public Health, Southern Medical University, Guangzhou 510515, China
³Department of Orthopedics, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou 510900, Guangdong, China
⁴Department of Orthopedics, The First People’s Hospital of Changde City, Changde 415003, Hunan, China
⁵Department of Orthopedics, Chenzhou No.1 People’s Hospital, Chenzhou 423000, Hunan, China

*Equal contribution

Correspondence to: Ziyuan Chen, Xungang Xiao, Gen Wu; email: 781893912@qq.com, https://orcid.org/0000-0003-0343-0439; xgx8088@163.com, https://orcid.org/0000-0001-9117-736X; wugen0728@163.com, https://orcid.org/0000-0001-8166-5474

Keywords: sarcoma, prognosis, expression level, GINS

Received: April 16, 2022 Accepted: July 5, 2022 Published: July 27, 2022

Copyright: © 2022 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**ABSTRACT**

Objective: This study was undertaken to explore the expression and prognostic value of GINS family in human sarcoma, as well as the association between the expression levels of the GINS family and sarcoma immune infiltration.

Results: We discovered that the mRNA expression levels of GINS1, GINS2, GINS3, and GINS4 were all higher in the majority of tumor tissues than in normal samples, of course, including sarcoma. Through the CCLE, all the four members expression were observed in high levels in sarcoma cell lines. In Gene Expression Profiling Analysis (GEPIA) and Kaplan-Meier Plotter, our results indicated that the poor overall survival (OS), disease-free survival (DFS) and relapse free survival (RFS) were tightly associated with the increased expression of GINS genes. In TIMER database, we found that highly expressed GINS was significantly correlated with the low infiltration level of CD4+ T cell and macrophage.

Conclusions: The four GINS family members were all the prognostic biomarkers for the prognosis of human sarcoma and can reduce the level of immune cell infiltration in the sarcoma microenvironment.

Methods: In terms of the expression levels of mRNA for GINS family members, a particular contrast in various cancers, especially human sarcoma, was conducted through ONCOMINE and GEPIA and CCLE databases. Kaplan-Meier Plotter was used to identify the prognostic value of GINS family in sarcoma. The relationship between the expression level of GINS and the infiltration of immune cells was analyzed in TIMER database.

**INTRODUCTION**

Sarcomas consist of a group of rare solid tumors of mesenchymal cell origin with distinct clinical and pathological features. Generally, they are divided into two categories: soft tissue sarcoma and osteosarcoma. Sarcomas account for approximately 1% of all adult malignancies and 15% of pediatric malignancies [1]. Osteosarcoma accounts for 20% of primary malignant bone tumors, it is the most common primary malignant
bone tumor in adolescents. 70%-80% of all the patients are 10-25 years old. The annual incidence rate is 1-3 people per 1 million people [2]. As the pathogenesis of osteosarcoma is still unclear, the 5-year survival rate of patients with osteosarcoma still hovers between 60% and 70% [3]. Soft tissue sarcomas (STS) (including fat, muscle, nerve and nerve sheath, blood vessel and other connective tissues) is classified according to similar tissue morphology. The STS classification reported by the World Health Organization in 2013 includes more than 50 histological subtypes, liposarcoma (LPS), and Differentiated sarcoma (US), leiomyosarcoma (LMS), myxofibrosarcoma (MFS) and synovial sarcoma (SS) are the most common types in adults [4]. Despite the development of surgery and adjuvant therapy, the treatment of sarcoma has improved [5], but the long-term survival rate of patients with high-grade sarcoma is still very low [6]. More than 50% of high-risk sarcoma patients will metastasize and die. Therefore, it is urgent to further explore the molecular mechanism of the occurrence and development of sarcoma [7].

CMG complex is composed of the Cdc45 protein, four subunits of the GINS complex (Psf1, Psf2, Psf3, and Sld5) and the heterohexamer minichromosome maintenance (MCM) 2-7 complex. It is most likely to be used as a replication helicase to unbind duplex DNA before the replication fork [8]. Recently, studies have shown that impaired function of the CMG complex will accelerate the development of genetic diseases [9]. The GINS complex consists of four subunits encoded by GINS1, GINS2, GINS3 and GINS4 genes. As a member of CMG, GINS complex plays important roles in the establishment of DNA replication forks and replisome progression. We knew that GINSs were highly expressed in many tumors and were associated with their prognosis. For example, GINS1 was found to be a potential biomarker for patients with CRC [10], and an inherited GINS1 deficiency was found to be one of the foundations of growth retardation [9]. GINS2 served as an independent risk factor for poor prognosis of early-stage cervical cancer through multivariate analysis [11]. Liu et al. found that GINS mRNA expression was significantly increased in patients with alcohol abuse. In experiments of mice, alcohol stimulated inflammatory cytokines and GINS2 knockdown further promoted them, while GINS2 knockdown promoted the alcohol-induced NF-κB activity of microglia, suggesting that GINS2 had a protective mechanism in alcohol-induced brain injury [12]. GINS3 has not only been linked to colon and lung cancer [13, 14], but also plays a central role in the euchromatic replicative helicase CMG (Cdc45-MCM helicase-GINS) [15]. GINS4 has also been associated with the progression and prognosis of lung and stomach cancer [16, 17]. However, to our best knowledge, there is no specific exploration about GINS with sarcoma.

RESULTS

Transcriptional levels of GINS members in sarcoma patients

Four members (GINS1, GINS2, GINS3, GINS4) of GINS family has been discovered in previous studies. They were found to be linked to many different types of tumor. The ONCOMINE database was used to compare the dissimilarity of transcription levels of GINS between cancer and normal samples. We detected that the transcription levels of GINS were upregulated in several cancers including cervical cancer, colorectal cancer, lung cancer and sarcoma. Especially, all the transcription levels of the four subunits of GINS were upregulated in sarcoma tissues (Figure 1). In Table 1, as we showed, the mRNA expression level of GINS1 was significantly upregulated in sarcoma patients. In Detwiller Sarcoma dataset [18], the mRNA expression of GINS1 in pleomorphic liposarcoma was higher than in normal samples, with a fold change of 10.222. In fibrosarcoma, malignant fibrous histiocytoma and round cell liposarcoma, GINS1 was also more highly expressed than in normal samples, and the fold changes were 9.773, 10.455 and 6.478. The Barretina Sarcoma dataset [19] provided us that the expression levels of GINS1 were higher in pleomorphic liposarcoma (fold change = 4.135), myxofibrosarcoma (fold change = 5.272), leiomyosarcoma (fold change = 4.566), dedifferentiated liposarcoma (fold change = 3.204) and myxoid/round cell liposarcoma (fold change = 3.412) than in normal samples.

We could also learn from the Detwiller et al. [18] that GINS2 was overexpressed in pleomorphic liposarcoma, malignant fibrous histiocytoma, fibrosarcoma, round cell liposarcoma with fold changes of 7.103, 6.800, 6.258 and 4.712 respectively. Highly expressed GINS2 was also found in Pleomorphic Liposarcoma, Myxofibrosarcoma, Leiomyosarcoma, Dedifferentiated Liposarcoma, Myxoid/round Cell Liposarcoma, with fold changes of 2.231, 2.729, 2.892, 2.046 and 2.351 respectively, compared with normal tissues through Barretina Sarcoma dataset [19]. GINS3 was found upregulated with a fold change of 5.246 in Malignant Fibrous Histiocytoma in Detwiller datasets [18]. In Detwiller datasets [18], highly overexpressed GINS4 was reported in Fibrosarcoma (fold change = 2.441).

Comparison of the expression of GINS mRNAs in sarcoma and normal tissues

Using the GEPIA dataset, we compared the expression of GINS mRNAs in sarcoma and normal tissues, it indicated that the expression levels of GINS1, GINS2 and GINS3 in sarcoma were statistically higher than in
normal samples. The expression level of GINS4 in sarcoma was also higher than in normal samples, but with no significance. (Figure 2A–2F).

**GINS translational factors expression in sarcoma cell lines**

By interrogating CCLE, we detected the transcription level of GINS members in many types of cancer cell lines, and got the conclusion that GINS1, GINS2, GINS3 and GINS4 were highly expressed in sarcoma cell lines including Ewing’s sarcoma, osteosarcoma and chondrosarcoma. (Figure 3A–3D).

### The prognostic value of GINS members in sarcoma

The GEPIA and Kaplan-Meier Plotter was used to make the investigation of the prognostic ability of GINS1, GINS2, GINS3 and GINS4 expression levels in sarcoma. We can see from the (Figure 4A–4C), increased GINS1-3 were found to be linked to poor overall survival (OS) (p<0.05), disease-free survival (DFS) (p<0.05) and relapse-free survival (RFS) (p<0.05). Nevertheless, increased GINS4 was discovered tend to have significant association with poor RFS. To sum up, GINS1-4 were prognostic factors for sarcoma.

| Analysis Type by Cancer       | GINS1 | GINS2 | GINS3 | GINS4 |
|-------------------------------|-------|-------|-------|-------|
|                               | Cancer vs Normal | Cancer vs Normal | Cancer vs Normal | Cancer vs Normal |
| Bladder Cancer                | 1     | 3     | 1     |       |
| Brain and CNS Cancer          | 3     | 1     | 4     | 1     |
| Breast Cancer                 | 6     | 12    | 1     | 1     |
| Cervical Cancer               | 3     | 4     | 1     | 1     |
| Colorectal Cancer             | 10    | 7     | 5     | 6     |
| Esophageal Cancer             | 2     | 1     | 1     | 1     |
| Gastric Cancer                | 2     | 2     | 1     |       |
| Head and Neck Cancer          | 4     |       |       |       |
| Kidney Cancer                 | 2     |       | 4     |       |
| Leukemia                      | 3     | 1     | 3     |       |
| Liver Cancer                  | 3     |       |       |       |
| Lung Cancer                   | 11    | 7     | 1     | 3     |
| Lymphoma                      | 5     | 3     | 1     |       |
| Melanoma                      |       |       |       |       |
| Myeloma                       |       |       |       |       |
| Other Cancer                  | 3     | 1     | 3     | 2     |
| Ovarian Cancer                | 3     | 2     | 1     | 1     |
| Pancreatic Cancer             | 1     |       |       |       |
| Prostate Cancer               |       |       |       |       |
| Sarcoma                       | 9     | 9     | 1     | 1     |
| Significant Unique Analyses   | 67    | 5     | 57    | 5     |
| Total Unique Analyses         | 413   | 374   | 375   | 340   |

![Figure 1. Transcription levels of GINS family genes in different tumors.](image-url)
GINS1 was positively correlated with low expression level of immune cells. The results showed that highly expressed GINS1 was significantly associated with low infiltration level of CD4+ T cell (Correlation coefficient (cor) = -0.234, p<0.05) and macrophage infiltration level (cor = -0.233, p<0.05). High expression level of GINS2 was significantly associated with low macrophage infiltration level (cor = -0.137, p<0.05). High GINS4 expression level was significantly correlated with low infiltration level of CD4+ T cell (cor = -0.175, p<0.05) (Figure 6).

**DISCUSSION**

Sarcoma was a series of rare solid tumors and prognosis of sarcoma was poor. Sarcoma has a high degree of malignancy and the survival of patients with sarcoma remains poor. Therefore, it’s urgently needed to find the early prognostic biomarkers for sarcoma. In this study, we observed that GINS family members were all the prognostic biomarkers for sarcoma and GINS family genes could reduce the level of immune cell infiltration in the sarcoma microenvironment. All these results
Figure 2. The expression of GINS mRNA levels in sarcoma and normal tissues. (A) The expression of GINS1 in tumor tissues. (B) The expression of GINS2 in tumor tissues. (C) The expression of GINS3 in tumor tissues. (D) The expression of GINS4 in tumor tissues. (E, F) The expression of GINS family genes in sarcoma tissue.
suggesting that GINS family genes may be potential biomarker for prognosis of sarcoma, which may be helpful for development of early prognostic biomarkers for sarcoma.

Bioinformatics analysis was a discipline using the methods of applied mathematics, informatics, statistics and computer science to study biology [21], mainly for biological mysteries of large and complex biological data [22]. Accordingly, we conducted our study using bioinformatics analysis. Previous study has reported the functional role of several GINS member in sarcoma [23–25]. This study used a bioinformatics approach to investigate the expression of the GINS family in sarcoma and its impact on the prognosis of sarcoma patients, and to further investigate the relationship with immune cell infiltration in the sarcoma microenvironment. Furthermore, we probed into the correlation of all GINS family in sarcoma and its co-expressed genes. Dense-isotope substitution experiments discovered that GINS complex is important element rather than a passing traveler in initiation and process of replication [26]. Due to our research, a conclusion can be drawn that all the four subunits of GINS are overexpressed in sarcoma tissues, compared with normal tissues. The four GINS family members could make contributions to the treatment to sarcoma. The high expression level of GINS1, GINS2 and GINS4 could reduce immune cell infiltration in the sarcoma microenvironment. Moreover, expression of all the four members encoding the subunits for GINS complex positively correlated with each other.

Due to previous study, Stable association of MCM complex and GINS complex form the CMG complex, which is responsible for the activity of DNA helicases [27]. The increased expression of GINS family members was involved in many different types of cancers and procedures [8–17]. It was associated with worse prognosis. Tang et al. discovered that the

Figure 3. Expression of GINS transcription factors in sarcoma cell lines. (A) The expression of GINS1 in sarcoma cell lines. (B) The expression of GINS2 in sarcoma cell lines. (C) The expression of GINS3 in sarcoma cell lines. (D) The expression of GINS4 in sarcoma cell lines.
inhibition of GINS1 expression significantly weakened the proliferation in vitro, but accelerated the apoptosis of deviant cells [28]. Therefore, they defined it as a target of osteosarcoma. We’ve described about that in mice experiment, knockdown of GINS1 expression caused inhibition of tumor growth [29]. On the contrary, overexpressed levels of GINS1 lead to high proliferation [30]. Through the research by Bu et al., the levels of GINS1 also in connected with the development of pancreatic cancer [31]. This is also confirmed by the research of Fu et al. [32]. Our study indicated that the value of GINS1 in prognosis of human sarcoma was confirmed by 131 sarcoma patients. With the increased expression levels, there are also significant differences in DFS and OS.

GINS2 also found to be associated with tumors, by regulating PI3K/Akt and MEK/ERK signaling pathways, GINS2 facilitated cell proliferation, migration, invasion, and EMT in NSCLC [33]. Tian et al. also determined the identification of GINS2 as the hub gene though the WGCNA and PPI network. GINS2 was also reported to take part in DNA replication and cell progression as a companion of Sld five 2 [34]. And another pathway has been found in non-small-cell lung cancer by Chi et al., it indicated that via p53/GADD45A pathway, GINS2 knockdown down-regulated cell proliferation, causes G2/M phase cell cycle arrest and augments apoptosis conversely. In human sarcoma, our results revealed that the expression level of GINS2 in sarcoma tissues was higher than it in normal tissues. By GEPIA dataset, we confirmed the prognosis value of GINS2, its increased expression was linked to poor DFS and OS.

As for GINS3, the expression level of Psf3, which is encoded by GIINS3, in the study of Tauchi et al. in 2016 [35], was found to be association with age, gender,
Figure 5. Genes co-expressed with the GINS gene family in human sarcoma tissues. (A) Co-expressed genes of the GINS gene family in sarcomas. (B) Correlation between members of the GINS gene family in tumors analyzed by GEPIA.
T factor, lymph node metastasis, stage and P factor in lung adenocarcinoma. Besides, poor DFS and OS were matched by higher expression of it [35]. After 3 years, they confirmed that Psf3 is the independent prognostic factor for lung adenocarcinoma through further discoveries by multivariate analysis. Additionally, they revealed that in the patients, who received postoperative chemotherapy, with high expression of Psf3 in stage I, the five-year survival rate was much greater. Conversely, the same result was not been observed in patients with low expression, which signified the Psf3 may serve as a biomarker of adjuvant tegafur-uracil administration to treat lung adenocarcinoma in stage I [36]. In another Japanese research, Psf3, as a member of CMG complex, accelerated excessive proliferation also in non-small-cell lung cancer [37]. These are consistent with our study, in human sarcoma, GINS3 may be a potential biomarker and its expression have influence on the prognosis.

GINS4 was also reported expressed higher in gastric cancer, non-small-cell lung cancer, colorectal cancer and breast cancer than normal tissues [16, 17, 38, 39]. There were different pathways, for example, in gastric cancer, via directly combination with Rac1/CDC42, GINS4 activated Rac1/CDC42 and then influence the downstream pathways [16]. In colorectal cancer, the KLF/GINS4 might be the crucial factor [17]. Our study found high expression of GINS4 in human sarcoma tissues, and it tended to have tight connection with OS and DFS, but failed to achieve significance.

The tumor microenvironment has a very important impact on the progression and recurrence of many types of cancer. Previous studies have demonstrated that immune cells in the tumor microenvironment can promote or suppress cancer activity and have been used as an important determinant of immunotherapy efficacy and clinical prognosis. In the present study, we found that the expression level of GINS gene was significantly correlated with the level of immune cell infiltration, suggesting that GINS gene can be used to assess the immune status of sarcoma. Our study provides additional evaluation indicators for the effectiveness of immunotherapy in sarcoma patients.

The efficiency and convenience of bioinformatics are obvious, the datasets we used helped us to unearth the expression and prognosis of GINS family in human sarcoma. There are also limitations of our study, we used almost every practicable data, it still seems to be inadequate, more future studies and more datasets are

![Figure 6. Association between GINS family genes and immune infiltration in sarcoma.](image-url)
needed. We didn’t find the pathways of GINS family in human sarcoma, and we will keep on and achieve Immunohistochemical experiments.

**CONCLUSIONS**

In conclusion, we observed that GINS family members were all highly expressed in sarcoma tissue and high expression of GINS members in sarcoma was closely related to sarcoma tumorigenesis. The prognostic relevance tested was also obvious, increased expression of GINS1, GINS2, GINS3 and GINS4 may provide us new therapeutic targets for the treatment of sarcoma. GINS1, GINS2 and GINS4 were positively correlated with the immune cell infiltration in sarcoma microenvironment. All the GINS members could be seen as potential prognostic and immune markers to improve prognostic accuracy of sarcoma.

**MATERIALS AND METHODS**

**ONCOMINE analysis**

The online data-mining platform and cancer microarray database ONCOMINE (https://www.oncomine.com/) was used to analyze the transcription levels of GINS members among different cancers [40]. P value was generated by the Student t-test, the cut-off of p-value and fold-change were defined as 0.05 and 2, respectively. and the mRNA expressions of the GINS family subunits in cancer samples was compared with normal ones. We also analyzed genes correlated with GINS members in sarcoma by using ONCOMINE [41].

**GEPIA analysis**

Gene Expression Profiling Interactive Analysis (GEPIA) (http://gepia.cancer-pku.cn/) is a newly developed multifunction data analysis platform based on the Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx). GEPIA includes 9736 tumors and 8587 normal samples. It was used to compare the different expression levels of GINS members between the human sarcomas and the normal samples. It also provided us survival analysis of sarcoma patients, including OS and DFS, the patients were divided into two groups according to the median expression of GINS (high and low expression). We also calculated log-rank P-value and the cox proportional hazard ratio (HR) with 95% confidence intervals [42, 43].

**Kaplan-Meier plotter**

Kaplan-Meier Plotter (http://www.kmplot.com) is an online database which includes the expression levels of different genes and their prognostic values in pan-cancer.

In our study, it was used to analyze the different relapse-free survival (RFS) of sarcoma patients with high GINS expression level and low GINS expression level. The hazard ratio (HR) with 95% confidence interval and the log-rank P-value were also calculated [44].

**CCLE dataset**

Cancer Cell Line Encyclopedia (CCLE) (https://portals.broadinstitute.org/ccle) was established to deeply and accurately depict the genetic characteristics of cancer. It was between the Broad Institute and the Novartis Institutes for Biomedical Research and its Genomics Institute of the Novartis Research Foundation. CCLE conducted a large-scale in-depth sequencing of 947 human cancer cell lines covering more than 30 tissue sources, integrating genetic information such as DNA mutations, gene expression and chromosome copy numbers. The CCLE was an access to provide us the genomic data, visualization cell lines. The GINS family’s expression in human sarcoma cell lines was obtained from the CCLE dataset [45].

**TIMER dataset analysis**

The TIMER database (https://cistrome.shinyapps.io/timer/) is a comprehensive resource for systematical analysis of immune infiltrates across diverse cancer types. In our study, it was used to analyze the correlation between the expression level of GINS family and infiltration level of immune cells.

**Availability of data and materials**

The datasets used and/or analyzed for this study were obtained from the ONCOMINE (https://www.oncomine.com/). Gene Expression Profiling Interactive Analysis (GEPIA) (http://gepia.cancer-pku.cn/), Kaplan-Meier Plotter (www.kmplot.com) and Cancer Cell Line Encyclopedia (CCLE) (https://portals.broadinstitute.org/ccle).

**Abbreviation**

GINS: Go, ichi, ni and san complex; CCLE: Cancer Cell Line Encyclopedia; GEPIA: Gene Expression Profiling Analysis; OS: overall survival; DFS: disease-free survival; RFS: relapse free survival; STS: Soft tissue sarcomas; LPS: liposarcoma; US: Differentiated sarcoma; LMS: leiomyosarcoma; MFS: myxofibrosarcoma; SS: synovial sarcoma; MCM: minichromosome maintenance; TCGA: the Cancer Genome Atlas; GTEx: Genotype-Tissue Expression; HR: hazard ratio; CCLE: Cancer Cell Line Encyclopedia.
AUTHOR CONTRIBUTIONS

GW and WW conceived, designed and conducted the experiments. GW and ZC wrote the paper. JZ, TW and ZC collected the data. KZ, QT, HZ, XX and TL edited the paper. KZ and JZ provided the research guide. JZ and WW supervised this project. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

The authors would like to thank all co-investigators, and colleagues who made this study possible.

CONFLICTS OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

FUNDING

This work was supported by the Mittal Innovation Project of Central South University (Grant No. GCX20190879Y), the Fundamental Research Funds for the Central Universities of Central South University (Grant No. 2018zzts930).

Editorial note

*This corresponding author has a verified history of publications using a personal email address for correspondence.

REFERENCES

1. Stiller CA, Craft AW, Corazziari I, and EUROCare Working Group. Survival of children with bone sarcoma in Europe since 1978: results from the EUROCare study. Eur J Cancer. 2001; 37:760–6. https://doi.org/10.1016/s0959-8049(01)00004-1 PMID:11311651

2. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010 (Suppl 7); 21:viii320–5. https://doi.org/10.1093/annonc/mdq276 PMID:20943636

3. Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF. The molecular pathogenesis of osteosarcoma: a review. Sarcoma. 2011; 2011:959248. https://doi.org/10.1155/2011/959248 PMID:21559216

4. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Keedy V, Kim E, Koon H, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018; 16:536–63. https://doi.org/10.6004/jnccn.2018.0025 PMID:29752328

5. Bourcier K, Le Cesne A, Tselikas L, Adam J, Mir O, Honore C, de Baere T. Basic Knowledge in Soft Tissue Sarcoma. Cardiovasc Intervent Radiol. 2019; 42:1255–61. https://doi.org/10.1007/s00270-019-02259-w PMID:31236647

6. Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AI, Honoré C, Fairweather M, Cannell A, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. Ann Surg. 2016; 263:1002–9. https://doi.org/10.1097/SLA.0000000000001447 PMID:26727100

7. Blay JY. Intensity of recent years in the investigation of soft tissue sarcoma. Future Oncol. 2017; 13:3–9. https://doi.org/10.2217/fon-2017-0119 PMID:28460535

8. Onesti S, MacNeill SA. Structure and evolutionary origins of the CMG complex. Chromosoma. 2013; 122:47–53. https://doi.org/10.1007/s00412-013-0397-x PMID:23412083

9. Cottineau J, Kottemann MC, Lach FP, Kang YH, Vély F, Deenick EK, Lazarov T, Gineau L, Wang Y, Farina A, Chansel M, Lorenzo L, Piperoglou C, et al. Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. J Clin Invest. 2017; 127:1991–2006. https://doi.org/10.1172/JCI90727 PMID:28414293

10. Bu F, Zhu X, Zhu J, Liu Z, Wu T, Luo C, Lin K, Huang J. Bioinformatics Analysis Identifies a Novel Role of GINS1 Gene in Colorectal Cancer. Cancer Manag Res. 2020; 12:11677–87. https://doi.org/10.2147/CMAR.S279165 PMID:32335499

11. Ouyang F, Liu J, Xia M, Lin C, Wu X, Ye L, Song L, Li J, Wang J, Guo P, He M. GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer. Oncol Rep. 2017; 37:2652–62. https://doi.org/10.3892/or.2017.5573 PMID:28405687

12. Liu C, Wang R, Zhang Y. GINS complex subunit 2 (GINS2) plays a protective role in alcohol-induced brain injury. Artif Cells Nanomed Biotechnol. 2019; 47:1–9.
13. Nagahama Y, Ueno M, Haraguchi N, Mori M, Takakura N. PSF3 marks malignant colon cancer and has a role in cancer cell proliferation. Biochem Biophys Res Commun. 2010; 392:150–4. https://doi.org/10.1016/j.bbrc.2009.12.174 PMID: 20059967

14. Hokka D, Maniwa Y, Tane S, Nishio W, Yoshiuma M, Okita Y, Obayashi C, Sakai Y, Chen X, Hayashi Y. Psf3 is a prognostic biomarker in lung adenocarcinoma. Lung Cancer. 2013; 79:77–82. https://doi.org/10.1016/j.lungcan.2012.10.001 PMID: 23127337

15. Boskovic J, Coloma J, Aparicio T, Zhou M, Robinson CV, Méndez J, Montoya G. Molecular architecture of the human GINS complex. EMBO Rep. 2007; 8:678–84. https://doi.org/10.1038/sj.embor.7401002 PMID: 17557111

16. Zhu Z, Yu Z, Rong Z, Luo Z, Zhang J, Qiu Z, Huang C. The novel GINS4 axis promotes gastric cancer growth and progression by activating Rac1 and CDC42. Theranostics. 2019; 9:8294–311. https://doi.org/10.7150/thno.36256 PMID: 31754397

17. Yang R, Liu N, Chen L, Jiang Y, Shi Y, Mao C, Liu Y, Wang M, Lai W, Tang H, Gao M, Xiao D, Wang X, et al. LSH interacts with and stabilizes GINS4 transcript that promotes tumorigenesis in non-small cell lung cancer. J Exp Clin Cancer Res. 2019; 38:280. https://doi.org/10.1186/s13046-019-1276-y PMID: 31253190

18. Detwiller KY, Fernando NT, Segal NH, Ryeom SW, D’Amore PA, Yoon SS. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res. 2005; 65:5881–9. https://doi.org/10.1158/0008-5472.CAN-04-0478 PMID: 15994966

19. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010; 42:715–21. https://doi.org/10.1038/ng.619 PMID: 20601955

20. Nakayama R, Mitani S, Nakagawa T, Hasegawa T, Kawai A, Morika H, Yabe H, Toyama Y, Ogose A, Toguchida J, Nakayama T, Yoshida T, Ichikawa H. Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol. 2010; 34:1599–607.

https://doi.org/10.1097/PAS.Ob013e3181f7ce2c PMID: 20975339

21. Pallen MJ. Microbial bioinformatics 2020. Microbiol Biotechnol. 2016; 9:681–6. https://doi.org/10.1111/1751-7915.12389 PMID: 27471065

22. Hiraoka S, Yang CC, Iwasaki W. Metagenomics and Bioinformatics in Microbial Ecology: Current Status and Beyond. Microbes Environ. 2016; 31:204–12. https://doi.org/10.1264/jsme2.ME16024 PMID: 27383682

23. Liu B, Liu Z, Wang Y, Lian X, Han Z, Cheng X, Zhu Y, Liu R, Zhao Y, Gao Y. Overexpression of GINS4 is associated with poor prognosis and survival in glioma patients. Mol Med. 2021; 27:117. https://doi.org/10.1186/s10020-021-00378-0 PMID: 34556022

24. Zhang Z, Chen P, Xie H, Cao P. Overexpression of GINS4 Is Associated With Tumor Progression and Poor Survival in Hepatocellular Carcinoma. Front Oncol. 2021; 11:654185. https://doi.org/10.3389/fonc.2021.654185 PMID: 33842367

25. Li H, Cao Y, Ma J, Luo L, Ma B. Expression and prognosis analysis of GINS subunits in human breast cancer. Medicine (Baltimore). 2021; 100:e24827. https://doi.org/10.1097/MD.00000000000024827 PMID: 33725952

26. Kamada K. The GINS complex: structure and function. Subcell Biochem. 2012; 62:135–56. https://doi.org/10.1007/978-94-007-4572-8_8 PMID: 22918584

27. Xuan F, Huang M, Zhao E, Cui H. MINA53 deficiency leads to glioblastoma cell apoptosis via inducing DNA replication stress and diminishing DNA damage response. Cell Death Dis. 2018; 9:1062. https://doi.org/10.1038/s41419-018-1084-x PMID: 30333481

28. Tang L, Yu W, Wang Y, Li H, Shen Z. Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma. Clin Transl Oncol. 2019; 21:1624–33. https://doi.org/10.1007/s12094-019-02090-2 PMID: 30963468

29. Nagahama Y, Ueno M, Miyamoto S, Morii E, Minami T, Mochizuki N, Saya H, Takakura N. PSF1, a DNA replication factor expressed widely in stem and progenitor cells, drives tumorigenic and metastatic properties. Cancer Res. 2010; 70:1215–24. https://doi.org/10.1158/0008-5472.CAN-09-3662 PMID: 20103637
30. Zhou L, Sun XJ, Liu C, Wu QF, Tai MH, Wei JC, Lei L, Meng FD, Qu K, Xu J. Overexpression of PSF1 is correlated with poor prognosis in hepatocellular carcinoma patients. Int J Biol Markers. 2015; 30:e56–64. https://doi.org/10.5301/jbm.5000105 PMID: 25198552

31. Bu F, Zhu X, Yi X, Luo C, Lin K, Zhu J, Hu C, Liu Z, Zhao J, Huang C, Zhang W, Huang J. Expression Profile of GINS Complex Predicts the Prognosis of Pancreatic Cancer Patients. Onco Targets Ther. 2020; 13:11433–44. https://doi.org/10.2147/OTT.S275649 PMID: 33192076

32. Fu Y, Zhou QZ, Zhang XL, Wang ZZ, Wang P. Identification of Hub Genes Using Co-Expression Network Analysis in Breast Cancer as a Tool to Predict Different Stages. Med Sci Monit. 2019; 25:8873–90. https://doi.org/10.12659/MSM.919046 PMID: 31758680

33. Liu X, Sun L, Zhang S, Zhang S, Li W. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling. J Cell Physiol. 2020; 235:7747–56. https://doi.org/10.1002/jcp.29381 PMID: 31681988

34. Tian W, Yang X, Yang H, Zhou B. GINS2 Functions as a Key Gene in Lung Adenocarcinoma by WGCNA Co-Expression Network Analysis. Onco Targets Ther. 2020; 13:6735–46. https://doi.org/10.2147/OTT.S255251 PMID: 32753902

35. Tauchi S, Sakai Y, Fujimoto S, Ogawa H, Tane S, Hokka D, Tanaka Y, Nishio W, Yoshimura M, Yanagita E, Itoh T, Hayashi Y, Maniwa Y. Psf3 is a prognostic biomarker in lung adenocarcinoma: a larger trial using tissue microarrays of 864 consecutive resections. Eur J Cardiothorac Surg. 2016; 50:758–64. https://doi.org/10.1093/ejcts/ezw077 PMID: 27005977

36. Kimura K, Tanaka Y, Tauchi S, Kitamura Y, Nishio W, Sakai Y, Hayashi Y, Yoshimura M, Maniwa Y. Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma. Thorac Cancer. 2019; 10:2300–7. https://doi.org/10.1111/1759-7714.13230 PMID: 31637868

37. Tane S, Sakai Y, Hokka D, Okuma H, Ogawa H, Tanaka Y, Uchino K, Nishio W, Yoshimura M, Maniwa Y. Significant role of Psf3 expression in non-small-cell lung cancer. Cancer Sci. 2015; 106:1625–34. https://doi.org/10.1111/cas.12770 PMID: 26291987

38. Rong Z, Luo Z, Zhang J, Li T, Zhu Z, Yu Z, Fu Z, Qiu Z, Huang C. GINS complex subunit 4, a prognostic biomarker and reversely mediated by Krüppel-like factor 4, promotes the growth of colorectal cancer. Cancer Sci. 2020; 111:1203–17. https://doi.org/10.1111/cas.14341 PMID: 32012389

39. Sagredo EA, Blanco A, Sagredo AI, Pérez P, Sepúlveda-Hermosilla G, Morales F, Müller B, Verdugo R, Marcelin K, Harismendy O, Armisén R. ADAR1-mediated RNA-editing of 3’UTRs in breast cancer. Biol Res. 2018; 51:36. https://doi.org/10.1186/s40659-018-0185-4 PMID: 30290838

40. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004; 6:1–6. https://doi.org/10.1016/j.oncom.2018.12.008

41. Sun CC, Zhou Q, Hu W, Li SJ, Zhang F, Chen ZL, Li G, Bi ZY, Bi YY, Gong FY, Bo T, Yuan ZP, Hu WD, et al. Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma. Aging (Albany NY). 2018; 10:973–87. https://doi.org/10.18632/aging.101441 PMID: 29754146

42. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45:W98–102. https://doi.org/10.1093/nar/gkx247 PMID: 28407145

43. Pan JH, Zhou H, Cooper L, Huang JL, Zhu SB, Zhao XX, Ding H, Pan YL, Rong L. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers. Front Immunol. 2019; 10:6. https://doi.org/10.3389/fimmu.2019.00006 PMID: 30761122

44. Hou GX, Liu P, Yang J, Wen S. Mining expression and prognosis of topoisomerase isofoms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter. PLoS One. 2017; 12:e0174515. https://doi.org/10.1371/journal.pone.0174515 PMID: 28355294

45. Sun CC, Li SJ, Chen ZL, Li G, Zhang Q, Li DJ. Expression and Prognosis Analyses of Runt-Related Transcription Factor Family in Human Leukemia. Mol Ther Oncolytics. 2018; 12:103–11. https://doi.org/10.1016/j.omto.2018.12.008 PMID: 30719500